A New Chapter for LunaVax: Expanding Vaccine Access Through Innovation
At LunaVax, we believe no child should be left behind because of where they live.
Across the world, millions of children and communities still lack access to life-saving vaccines, a gap we are determined to help close.
We’re excited to announce a major step forward in our journey:
Beginning this fall, LunaVax will join a pilot collaboration with Harvard Medical School’s GCSRT program to develop the Phase III protocol and regulatory framework for Nigeria’s first and one of the world’s pioneering microneedle vaccine patch (MAP) studies.
This collaboration marks a key step toward evidence-based readiness for future field implementation and local production.
The initiative, entering its preparation phase in October 2025, will focus on evaluating the community-based delivery of microneedle vaccine patches for measles immunization in underserved regions of Nigeria. The study will assess feasibility, acceptability, and coverage compared to traditional needle-and-syringe methods. It will do so by partnering with local health workers and health facilities, supported by mobile immunization vans and trusted community hubs.
It will also pilot the use of biometric tools for patient identification and vaccine tracking, helping ensure that no one is left behind.
If successful, this model could offer a scalable blueprint for expanding access to routine childhood vaccines across the continent, while creating a credible route to WHO prequalification and sustainable local production in Nigeria.
This initiative focuses on exploring next-generation solutions to improve vaccine accessibility, including the use of microneedle vaccine patches, mobile immunization delivery models, and biometric technology for improved patient identification and continuity of care. Our goal is simple yet urgent:
Bring vaccines closer to the communities that need them most. Faster, safer, and more equitably.
By combining local innovation with global research expertise, LunaVax is committed to reimagining how vaccines reach underserved populations, starting with Nigeria and expanding across Africa.
Through this collaboration, we aim to unlock smarter immunization systems that can reshape the future of public health.
Interested in contributing or learning more? Reach us at: pilotstudy@lunavax.com — we’d love to hear from you.
As we embark on this next chapter, we invite global health leaders, partners, funders, and innovators to join us. From patches to biometrics, we’re building a new blueprint for equitable immunization, one designed for the realities of local communities.
Together, we can rewrite the story of vaccine access and build a healthier future for every child, everywhere.
Follow our journey on LinkedIn and be part of the story.
#BeLunacious